Recalling what we thought we knew about recall periods: a qualitative descriptive study of how adults diagnosed with cancer use recall periods for patient-reported outcome items about physical function.

Autor: Coles T; Center for Health Measurement, Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA. Theresa.Coles@Duke.edu., Plyler K; Center for Health Measurement, Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA., Hernandez A; Center for Health Measurement, Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA., Fillipo R; Center for Health Measurement, Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA., Henke DM; Center for Health Measurement, Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA., Arizmendi C; Center for Health Measurement, Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA.; AstraZeneca, Evinova, Durham, NC, USA., Goodwin CR; Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA., LeBlanc TW; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA., Lagoo-Deenadayalan S; Department of Surgery, Duke University School of Medicine, Durham, NC, USA., Reeve BB; Center for Health Measurement, Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA., Weinfurt KP; Center for Health Measurement, Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA.
Jazyk: angličtina
Zdroj: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2024 Dec 04. Date of Electronic Publication: 2024 Dec 04.
DOI: 10.1007/s11136-024-03847-1
Abstrakt: Objectives: In cancer studies, assessment of patients' physical function can provide insight into cancer-related symptoms and the side effects of treatment. Physical function can be assessed using patient-reported outcome measures (PROMs), which may or may not include a recall period-the amount of time the questionnaire asks the respondent to think back to answer the questions. More understanding is needed about how patients interpret and respond to items posed with different recall periods, and which recall period they actually use.
Study Design and Setting: We conducted a qualitative study with 72 adults diagnosed with cancer to describe response processes when answering PROM items about physical function.
Results: When describing their physical function during concept elicitation interviews, most participants recalled their functioning over 1 month or more. When presented with PROM items with no recall period, the most used period was more than 4 weeks. When presented with a 7-day recall, the most used period was 7 days. However, almost 30% of responses used recall periods greater than 1 week.
Conclusion: Including a 7-day recall period improves recall consistency for patients when answering physical function PROM items, but there is still room for improvement. The inaccuracy of recall for PROMs in clinical trials influences the ability to calculate the change in treatment outcomes over time and may conceal or emphasize actual treatment effects.
Competing Interests: Declarations. Conflict of interest: TC has research funding from Merck and Pfizer; a prior consulting agreement with Regenxbio; and received a speaking honorarium from ISPOR. CA was a fellow at Duke (2021–2023) funded by AstraZeneca and is now an employee at AstraZeneca (2023-present). CRG is a consultant for Stryker and Medtronic. BBR had a consulting role with Novartis. TWL has received honoraria for consulting/advisory boards from AbbVie, Agilix, Agios/Servier, Apellis, Astellas, AstraZeneca, BlueNote, BMS/Celgene, Genentech, GSK, Lilly, Meter Health, Novartis, and Pfizer; speaking related honoraria from AbbVie, Agios, Astellas, BMS/Celgene, Incyte, and Rigel; equity interest in Dosentrx (stock options in a privately-held company); royalties from UpToDate; research funding from the AbbVie, American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, GSK, Jazz Pharmaceuticals, and Seattle Genetics. TWL is a Scholar in Clinical Research of the Leukemia & Lymphoma Society. BBR has received honoraria for participating in a meeting with Novartis. All other authors have no disclosures.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: